Description

Balchem’s $650 Million War Chest: Can Acquisitions Unlock Its Next Growth Phase?

Balchem Corporation reported record third-quarter results marked by broad-based growth across its three reporting segments: human nutrition and health, animal nutrition and health, and specialty products. Consolidated revenue reached $291 million, an 8.6% increase year-over-year, accompanied by a 16% rise in net income to $47 million and a 12.4% rise in adjusted EBITDA to a record $80 million. The company’s gross margin expanded by 70 basis points to 36.4%, reflecting benefits from higher sales, a favorable product mix, and manufacturing efficiencies, although partially offset by inflationary pressures on input costs. Operating expenses increased slightly due to higher compensation-related costs. Within segments, human nutrition and health recorded $188 million in sales, up 8.1%, driven by growth in both nutrients and food ingredients businesses. Earnings here increased nearly 12%, supported by favorable sales mix despite higher operating expenses. Animal nutrition and health saw an 11.